WuXi STA expands to Europe with purchase of BMS facility
CDMO to take over operations, including equipment and workforce, at site in Couvet, Switzerland
WuXi STA—a subsidiary of WuXi AppTec and a contract development and manufacturing organization (CDMO) serving the life sciences industry—has agreed to purchase Bristol Myers Squibb’s manufacturing facility in Couvet, Switzerland. This site marks the CDMO's first facility in Europe.
Subject to regulatory approvals and the satisfaction of other closing conditions, the companies envision a Q2 closing date. At this point, WuXi STA will acquire the Couvet site’s operations and assets, which include the plant and equipment, as well as inheriting a technically experienced workforce. The Couvet facility will continue to operate as part of the biopharma company’s manufacturing network until the deal is official.
Dr. Minzhang Chen, CEO of WuXi STA, is looking forward to the business potential that this acquisition provides European regions.
“We are pleased to add the Couvet manufacturing facility to our growing global manufacturing site network, and look forward to working with the talented team who share our focus on excellence and a patient-centered approach,” he said. “The acquisition will allow WuXi STA to better serve European markets and support our global customers to deliver innovative medicines and treatments to patients around the world.”
